Pricing & Reimbursement
Our vision is that all patients with chronic and/or lifelong conditions in the EU have access to high quality, patient-centred equitable health and social care. There is an urgent need to identify effective and concrete actions at EU level to close the current gap on health inequalities, so that all patients across Europe have access to high-quality, affordable treatments.
In June 2016, EPF published a statement outlining the nine core principles from the patients' perspective on the value and pricing of innovative medicines. The statement can be consulted here.
Contact: Kaisa Immonen, Director of Policy.
On 1 July 2020 EPF launched our latest position paper entitled ‘The Value and Pricing of Innovative Medicines.’ In the context of current political priorities on ensuring access to affordable medicines and a forthcoming new Pharmaceutical Strategy for Europe, our paper contributes EPF’s perspective as a cross-disease umbrella patient organisation to the EU-level and international debate on prices and value of innovative medicines, building on our core principles of 2016 (above).